Brahim Redouane1, Stephen J Greene2, Marat Fudim2, Muthiah Vaduganathan3, Andrew P Ambrosy4, Jie-Lena Sun2, Adam D DeVore2, Steven E McNulty2, Robert J Mentz2, Adrian F Hernandez2, G Michael Felker2, Lauren B Cooper5, Barry A Borlaug6, Eric J Velazquez7, Kenneth B Margulies8, Abhinav Sharma1. 1. McGill University Health Centre, McGill University, Montreal, QC, Canada (B.R., A.S.). 2. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (S.J.G., M.F., J.-L.S., A.D.D, S.E.M., R.J.M., A.F.H., G.M.F.). 3. Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA (M.V.). 4. Division of Cardiology, The Permanente Medical Group, San Francisco, CA (A.P.A.). 5. Inova Heart and Vascular Institute, Falls Church, VA (L.B.C.). 6. Division of Circulatory Failure, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.). 7. Yale University School of Medicine, New Haven, CT (E.J.V.). 8. Perelman School of Medicine, University of Pennsylvania, Philadelphia (K.B.M.).
Abstract
BACKGROUND: The FIGHT (Functional Impact of GLP-1 [glucagon-like peptide-1] for Heart Failure Treatment) trial randomized 300 patients with heart failure with reduced ejection fraction (HFrEF) and a recent hospitalization for heart failure toliraglutide versus placebo. While there was no difference in the primary outcome (rank score of time to death, time to rehospitalization for heart failure, and change in NT-proBNP [N-terminal pro-B-type natriuretic peptide]), there was a significant increase in cystatin C among patients randomized to liraglutide raising concern of adverse renal outcomes. We performed a post hoc analysis of FIGHT to investigate whether liraglutide was associated with worsening renal function (WRF). METHODS: The relationship between randomization to liraglutide and WRF was evaluated using logistic regression models. Two hundred seventy-four patients (91%) had complete data to assess for WRF defined as: increase in SCr ≥0.3 mg/dL, or ≥25% decrease in estimated glomerular filtration rate, or an increase in cystatin C ≥0.3 mg/L from baseline to 180-days. RESULTS:Patients with WRF (n=113, 41%), compared with those without, were older, had more comorbidities, and lower utilization of guideline-directed medical treatment. Logistic regression models showed that age and baseline cystatin C levels were associated with WRF. In adjusted models, liraglutide was not associated with excess risk of WRF compared with placebo (odds ratio, 1.02 [95% CI, 0.62-1.67]). There was also no difference in the rank score when WRF was added as a fourth-tier outcome. CONCLUSIONS:Liraglutide was not associated with WRF among patients with HFrEF and a recent hospitalization for heart failure. These data support the relative renal safety profile of liraglutide among patients with HFrEF. Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01800968.
RCT Entities:
BACKGROUND: The FIGHT (Functional Impact of GLP-1 [glucagon-like peptide-1] for Heart Failure Treatment) trial randomized 300 patients with heart failure with reduced ejection fraction (HFrEF) and a recent hospitalization for heart failure to liraglutide versus placebo. While there was no difference in the primary outcome (rank score of time to death, time to rehospitalization for heart failure, and change in NT-proBNP [N-terminal pro-B-type natriuretic peptide]), there was a significant increase in cystatin C among patients randomized to liraglutide raising concern of adverse renal outcomes. We performed a post hoc analysis of FIGHT to investigate whether liraglutide was associated with worsening renal function (WRF). METHODS: The relationship between randomization to liraglutide and WRF was evaluated using logistic regression models. Two hundred seventy-four patients (91%) had complete data to assess for WRF defined as: increase in SCr ≥0.3 mg/dL, or ≥25% decrease in estimated glomerular filtration rate, or an increase in cystatin C ≥0.3 mg/L from baseline to 180-days. RESULTS:Patients with WRF (n=113, 41%), compared with those without, were older, had more comorbidities, and lower utilization of guideline-directed medical treatment. Logistic regression models showed that age and baseline cystatin C levels were associated with WRF. In adjusted models, liraglutide was not associated with excess risk of WRF compared with placebo (odds ratio, 1.02 [95% CI, 0.62-1.67]). There was also no difference in the rank score when WRF was added as a fourth-tier outcome. CONCLUSIONS: Liraglutide was not associated with WRF among patients with HFrEF and a recent hospitalization for heart failure. These data support the relative renal safety profile of liraglutide among patients with HFrEF. Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01800968.
Authors: Søren L Kristensen; Rasmus Rørth; Pardeep S Jhund; Kieran F Docherty; Naveed Sattar; David Preiss; Lars Køber; Mark C Petrie; John J V McMurray Journal: Lancet Diabetes Endocrinol Date: 2019-08-14 Impact factor: 32.069
Authors: John E A Blair; Peter S Pang; Robert W Schrier; Marco Metra; Brian Traver; Thomas Cook; Umberto Campia; Andrew Ambrosy; John C Burnett; Liliana Grinfeld; Aldo P Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Marvin A Konstam; Mihai Gheorghiade Journal: Eur Heart J Date: 2011-07-23 Impact factor: 29.983
Authors: Kenneth B Margulies; Adrian F Hernandez; Margaret M Redfield; Michael M Givertz; Guilherme H Oliveira; Robert Cole; Douglas L Mann; David J Whellan; Michael S Kiernan; G Michael Felker; Steven E McNulty; Kevin J Anstrom; Monica R Shah; Eugene Braunwald; Thomas P Cappola Journal: JAMA Date: 2016-08-02 Impact factor: 56.272
Authors: Shannon M Dunlay; Michael M Givertz; David Aguilar; Larry A Allen; Michael Chan; Akshay S Desai; Anita Deswal; Victoria Vaughan Dickson; Mikhail N Kosiborod; Carolyn L Lekavich; Rozalina G McCoy; Robert J Mentz; Ileana L Piña Journal: Circulation Date: 2019-06-06 Impact factor: 29.690
Authors: H M Krumholz; Y T Chen; V Vaccarino; Y Wang; M J Radford; W D Bradford; R I Horwitz Journal: Am J Cardiol Date: 2000-05-01 Impact factor: 2.778
Authors: Johannes F E Mann; David D Ørsted; Kirstine Brown-Frandsen; Steven P Marso; Neil R Poulter; Søren Rasmussen; Karen Tornøe; Bernard Zinman; John B Buse Journal: N Engl J Med Date: 2017-08-31 Impact factor: 91.245
Authors: Muthiah Vaduganathan; Ravi B Patel; Avinainder Singh; Cian P McCarthy; Arman Qamar; James L Januzzi; Benjamin M Scirica; Javed Butler; Christopher P Cannon; Deepak L Bhatt Journal: J Am Coll Cardiol Date: 2019-04-02 Impact factor: 24.094
Authors: Xavier Pi-Sunyer; Arne Astrup; Ken Fujioka; Frank Greenway; Alfredo Halpern; Michel Krempf; David C W Lau; Carel W le Roux; Rafael Violante Ortiz; Christine Bjørn Jensen; John P H Wilding Journal: N Engl J Med Date: 2015-07-02 Impact factor: 91.245
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079